|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM190230126 |
| 003 |
DE-627 |
| 005 |
20231223185006.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2009 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2009.06.010
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0634.xml
|
| 035 |
|
|
|a (DE-627)NLM190230126
|
| 035 |
|
|
|a (NLM)19631585
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Sharabi, Amir
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A tolerogenic peptide that induces suppressor of cytokine signaling (SOCS)-1 restores the aberrant control of IFN-gamma signaling in lupus-affected (NZB x NZW)F1 mice
|
| 264 |
|
1 |
|c 2009
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 08.10.2009
|
| 500 |
|
|
|a Date Revised 03.12.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Interferon-gamma (IFN-gamma) plays a pathogenic role in systemic lupus erythematosus (SLE). Uncontrolled IFN-gamma signaling may result from a deficiency in the negative regulator, namely, suppressor of cytokine signaling-1 (SOCS-1). We investigated the activation status of IFN-gamma signaling pathway in SLE-afflicted (New-Zealand-BlackxNew-Zealand-White)F1 mice and determined its responsiveness when treating with a tolerogenic peptide, hCDR1, which ameliorates SLE. SOCS-1 was suppressed and pSTAT1 was enhanced in spleen-derived cells from SLE-affected mice as compared with healthy controls. Treatment with hCDR1 reversed the expression of these two molecules in association with clinical amelioration. In vitro stimulation with IFN-gamma resulted in elevated levels of SOCS-1 in cells from both vehicle and hCDR1-treated mice but this effect reached significance only in cells of the latter group, which also exhibited reduced levels of pSTAT1. Thus, SOCS-1 is diminished in SLE-affected mice, and treatment with hCDR1 results in its up-regulation thereby restoring control of IFN-gamma signaling pathway
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Autoantigens
|2 NLM
|
| 650 |
|
7 |
|a CDR1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Nerve Tissue Proteins
|2 NLM
|
| 650 |
|
7 |
|a Peptides
|2 NLM
|
| 650 |
|
7 |
|a STAT1 Transcription Factor
|2 NLM
|
| 650 |
|
7 |
|a Socs1 protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a Stat1 protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a Suppressor of Cytokine Signaling 1 Protein
|2 NLM
|
| 650 |
|
7 |
|a Suppressor of Cytokine Signaling Proteins
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a Sthoeger, Zev M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mahlab, Keren
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lapter, Smadar
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zinger, Heidy
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mozes, Edna
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 133(2009), 1 vom: 01. Okt., Seite 61-8
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:133
|g year:2009
|g number:1
|g day:01
|g month:10
|g pages:61-8
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2009.06.010
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 133
|j 2009
|e 1
|b 01
|c 10
|h 61-8
|